Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement.
Hatef Darabi, Kamila Czene, Wanting Zhao...
https://pubmed.ncbi.nlm.nih.gov/22314178/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-09-21
100000
Participants Needed
11
Research Sites
N/A
Total Duration
Researchers are evaluating a new approach to breast cancer screening that personalizes recommendations based on individual risk factors rather than the traditional one-size-fits-all annual mammogram starting at age 40. This study compares annual screening to a risk-based schedule that considers personal and family history, breast density, and genetic testing. The goal is to reduce false positives, unnecessary biopsies, and overdiagnosis while maintaining early cancer detection. The study includes women ages 30 to 74, with those aged 30 to 39 only eligible for the personalized screening arm. Participants are assigned to one of two groups the Annual Arm, which follows standard annual mammograms and basic risk assessment, or the Risk-Based Arm, which involves a comprehensive risk assessment including genetic testing of nine genes and a panel of SNPs to tailor screening frequency, start, and stop dates. All participants complete health questionnaires and receive screening advice based on their assigned risk assessment method. Notably, the study allows participants to choose their screening arm rather than being randomized. During the study, participants provide saliva samples for genetic testing and complete questionnaires. Researchers will monitor outcomes such as late-stage cancer rates and biopsy rates over at least five years. Additional measures include breast imaging rates, cancer anxiety, and adherence to screening schedules. The study aims to provide personalized screening schedules that optimize benefits and reduce harms. Participation may last up to ten years, with ongoing data collection to evaluate long-term effects and screening safety.
CONDITIONS
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
A
Allison Fiscalini, MPH
J
Jennifer Atamer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Personalized, risk-based breast cancer screening | Standard annual breast cancer screening |
|---|---|---|
| What it is | A screening approach that uses an individual's health history and genetic testing to assess breast cancer risk, then recommends a personalized mammography screening plan tailored to that risk. | Standard guideline-based approach where all eligible women receive mammograms every year, regardless of their individual estimated risk. |
| Role in the trial | Intervention arm—participants randomised to this group received screening recommendations based on their personalized risk profile. | Active comparator—participants randomised to this group followed annual mammography screening regardless of personal risk factors. |
| Primary use | To detect breast cancer while potentially reducing unnecessary screening and procedures by individualizing frequency and timing based on risk. | To detect breast cancer early through consistent, routine yearly mammograms for all eligible participants. |
| How it is given or performed | Participants complete a detailed questionnaire and provide a saliva sample for genetic analysis. Screening schedule is personalized and communicated based on their combined risk profile. | Participants undergo annual mammography screening, following the routine schedule for their age group without consideration of personal or genetic risk. |
| Evidence status | Evaluated in a large randomized trial; ongoing reporting on effectiveness, impact on cancer stage at diagnosis, and rates of unnecessary biopsies. | Long-established method with robust evidence for reducing breast cancer mortality, but associated with high biopsy rates and potential for overdiagnosis. |
| Important limitations | Not all risk factors can be fully captured with available risk scores or genetic data; there may be uncertainties about long-term impact on cancer outcomes. | Annual screening can lead to the detection of indolent or non-threatening cancers, increased false positives, and unnecessary biopsies or anxiety. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual)
Duration - Ongoing throughout participation
Participants complete health questionnaires and provide saliva samples for genetic testing if in the risk-based screening arm. They receive screening schedule recommendations based on their assigned screening method.
Periodic visits as needed for sample collection and counseling
Duration - Up to 10 years
Participants follow their personalized or annual mammogram screening schedules and complete ongoing assessments including questionnaires about anxiety and adherence.
Regular screening visits according to assigned schedule
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hatef Darabi, Kamila Czene, Wanting Zhao...
https://pubmed.ncbi.nlm.nih.gov/22314178/Kirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner...
https://pubmed.ncbi.nlm.nih.gov/41385723/Laura J Esserman, Ian M Thompson, Brian Reid...
https://pubmed.ncbi.nlm.nih.gov/24807866/Kirkpatrick B Fergus, Rachel S Heise, Lisa Madlensky...
https://pubmed.ncbi.nlm.nih.gov/40877879/Katherine Leggat-Barr, Rita Ryu, Michael Hogarth...
https://pubmed.ncbi.nlm.nih.gov/37607323/E B Claus
https://pubmed.ncbi.nlm.nih.gov/14574179/Elissa M Ozanne, Caroline Annis, Kelly Adduci...
https://pubmed.ncbi.nlm.nih.gov/17319855/Laura J Esserman, Allison S Fiscalini, Arash Naeim...
https://pubmed.ncbi.nlm.nih.gov/41385349/J P Costantino, M H Gail, D Pee...
https://pubmed.ncbi.nlm.nih.gov/10491430/Jonathan Tyrer, Stephen W Duffy, Jack Cuzick
https://pubmed.ncbi.nlm.nih.gov/15057881/University of California, San Francisco
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor